RxDoctor Payments Data

Scott Pollak, MD

Clinical Cardiac Electrophysiology · Orlando, FLNPI 1629062245

Payments from drug & device makers

$49,130in general payments, 2019–2025

Across 47 payments — averaging $1045.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$42K
  • Biosense Webster, Inc.$3K
  • Abbott$3K
  • Medtronic$184
  • Astellas Pharma US Inc$100
  • Irhythm Technologies, Inc.$70
  • plus $314 from 11 others

What the payments were for

  • Consulting fees$10,83089%
  • Travel & lodging$2042%
  • Food & beverage$1,0489%
  • Education$1221%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,130 in reported general payments places this provider in the 60th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$758,799
Medicare patients
915
Services billed
6,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban679$756,328
XareltoRivaroxaban203$241,470
MultaqDronedarone Hcl61$105,250
EntrestoSacubitril/Valsartan61$65,438
Repatha SureclickEvolocumab57$58,130
JardianceEmpagliflozin49$52,950
PradaxaDabigatran Etexilate Mesylate11$5,880
Metoprolol Succinate444$5,784
Diltiazem 24hr Er (Cd)Diltiazem Hcl95$4,727
Ranolazine ErRanolazine32$4,700
Rosuvastatin Calcium261$3,363
Atorvastatin Calcium246$2,981
Carvedilol240$2,335
Flecainide Acetate47$2,040
Ezetimibe54$1,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$756,328679 claims
NovartisEntresto$20$65,43861 claims
Boehringer IngelheimJardiance, Pradaxa$44$58,83060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →